Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Syndax's Revuforj (Revumenib) Added To NCCN Guidelines As Category 2A Treatment For Relapsed/Refractory NPM1 Mutated AML; Supported By AUGMENT-101 Trial, FDA Priority Review sNDA Decision Due Oct. 25, 2025

Author: Benzinga Newsdesk | September 19, 2025 06:02am

Posted In: SNDX